Kaempferol prevents Nrf2 from ubiquitin-mediated proteolysis to mitigate both NLRP3 inflammation and oxidative stress: implications for alleviating DSS-induced colitis in mice
- 4 October 2025
- journal article
- research article
- Published by Springer Nature in Inflammopharmacology
- Vol. 33 (11) , 6861-6876
Abstract
Background Activation of the NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome and oxidative stress are key pathological hallmarks of inflammatory bowel disease (IBD) and represent novel targets for therapeutic intervention. The therapeutic potential of the naturally occurring flavonoid kaempferol (KAE) in IBD, along with its underlying molecular mechanisms, remains incompletely understood. Methods We established dextran sulfate sodium (DSS)-induced colitis and lipopolysaccharide (LPS)-induced systemic inflammation mouse models. KAE was administered as an intervention. In vitro, peritoneal macrophages (PMs) were stimulated to activate the NLRP3 inflammasome. We comprehensively evaluated the effects of KAE on interleukin-1β (IL-1β) release, NLRP3 inflammasome assembly, and mitochondrial reactive oxygen species (mt-ROS) production. Additionally, we assessed its impact on the Keap1-Nrf2 pathway. Molecular docking and ubiquitin-dependent degradation assays were conducted to confirm Nrf2 as a direct target of KAE. Results KAE significantly attenuated colitis development, marked by reduced NLRP3 expression and enhanced Nrf2 activation. It inhibited both the priming and assembly phases of NLRP3 inflammasome activation. Notably, Nrf2 inhibition completely abolished KAE-mediated removal of mt-ROS and downstream suppression of NLRP3 inflammasome activation. Mechanistically, KAE prevented Nrf2 proteolysis by directly binding to Arg415 of Keap1. Conclusions Our findings demonstrate that KAE acts as an mt-ROS scavenger to protect against inflammatory pyroptosis, offering novel mechanistic insights and a promising therapeutic strategy for colitis treatment.Keywords
Funding Information
- Key Technologies Research and Development Program (2023YFC3502801)
- National Natural Science Foundation of China (82304755)
- Medical Science and Technology Project of Zhejiang Province (2024ZL343)
This publication has 49 references indexed in Scilit:
- Molecular mechanisms regulating NLRP3 inflammasome activationCellular & Molecular Immunology, 2015
- Cancers Complicating Inflammatory Bowel DiseaseNew England Journal of Medicine, 2015
- Structure of the BTB Domain of Keap1 and Its Interaction with the Triterpenoid Antagonist CDDOPLOS ONE, 2014
- Oxidized Mitochondrial DNA Activates the NLRP3 Inflammasome during ApoptosisImmunity, 2012
- A role for mitochondria in NLRP3 inflammasome activationNature, 2010
- Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasomeGut, 2010
- Cutting Edge: NF-κB Activating Pattern Recognition and Cytokine Receptors License NLRP3 Inflammasome Activation by Regulating NLRP3 ExpressionThe Journal of Immunology, 2009
- Increased Susceptibility of Nrf2 Knockout Mice to Colitis-Associated Colorectal CancerCancer Prevention Research, 2008
- Nrf2 gene promoter polymorphism is associated with ulcerative colitis in a Japanese population.2008
- Nrf2-Deficient Mice Have an Increased Susceptibility to Dextran Sulfate Sodium–Induced ColitisCancer Research, 2006